Greenwich LifeSciences: Phase 3 Targeting Recurrent Breast Cancer
Jan. 29, 2021
Greenwich LifeSciences (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. In a prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites) Phase IIb clinical trial led by MD Anderson, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up. Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 immunotherapy was well tolerated, and no serious adverse events were reported related to the GP2 immunotherapy. Visit https://www.GLSIinfo.com to learn more.
